CRISPR Therapeutics AG
CRSPFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
35
Cost of Revenue
110
Gross Profit
-75
Gross Margin
-215.0%
Operating Income
-467
Operating Margin
-1333.0%
Net Income
-366
Net Margin
-1046.4%
EPS (Basic)
$-4.34
EPS (Diluted)
$-4.34
EBITDA
-447
EBITDA Margin
-1278.0%
2023
12/31/2023
Revenue
370
Cost of Revenue
130
Gross Profit
240
Gross Margin
64.8%
Operating Income
-223
Operating Margin
-60.1%
Net Income
-154
Net Margin
-41.5%
EPS (Basic)
$-1.94
EPS (Diluted)
$-1.94
EBITDA
-203
EBITDA Margin
-54.8%
2022
12/31/2022
Revenue
0
Cost of Revenue
110
Gross Profit
-110
Gross Margin
-25186.7%
Operating Income
-673
Operating Margin
-154394.7%
Net Income
-650
Net Margin
-149122.7%
EPS (Basic)
$-8.36
EPS (Diluted)
$-8.36
EBITDA
-649
EBITDA Margin
-148850.7%
2021
12/31/2021
Revenue
913
Cost of Revenue
101
Gross Profit
812
Gross Margin
88.9%
Operating Income
374
Operating Margin
40.9%
Net Income
378
Net Margin
41.4%
EPS (Basic)
$4.97
EPS (Diluted)
$4.70
EBITDA
391
EBITDA Margin
42.9%
2020
12/31/2020
Revenue
1
Cost of Revenue
269
Gross Profit
-269
Gross Margin
-37369.7%
Operating Income
-354
Operating Margin
-49295.5%
Net Income
-349
Net Margin
-48520.9%
EPS (Basic)
$-5.29
EPS (Diluted)
$-5.29
EBITDA
-345
EBITDA Margin
-48018.2%